Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial
Covered in this story
Call it yourself
No calls on $FATE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Fate Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.